SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 277 filers reported holding SAGE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 1.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,909,497 | -80.3% | 141,375 | -54.9% | 0.00% | -80.0% |
| Q2 2023 | $14,738,372 | +251150.8% | 313,449 | +124.2% | 0.01% | +150.0% |
| Q1 2023 | $5,866 | -2.4% | 139,785 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $6,008 | -99.9% | 157,541 | -13.9% | 0.00% | -33.3% |
| Q3 2022 | $7,168,000 | +18.8% | 183,043 | -2.1% | 0.00% | +50.0% |
| Q2 2022 | $6,036,000 | -20.7% | 186,892 | -17.5% | 0.00% | 0.0% |
| Q1 2022 | $7,614,000 | -27.7% | 226,603 | -8.5% | 0.00% | -33.3% |
| Q4 2021 | $10,534,000 | +1.1% | 247,614 | +5.3% | 0.00% | 0.0% |
| Q3 2021 | $10,415,000 | -19.0% | 235,051 | +3.8% | 0.00% | -25.0% |
| Q2 2021 | $12,865,000 | -4.2% | 226,444 | +26.2% | 0.00% | 0.0% |
| Q1 2021 | $13,433,000 | -30.1% | 179,468 | -19.3% | 0.00% | -42.9% |
| Q4 2020 | $19,231,000 | +24.0% | 222,300 | -12.4% | 0.01% | +16.7% |
| Q3 2020 | $15,509,000 | +33.0% | 253,751 | -9.5% | 0.01% | +20.0% |
| Q2 2020 | $11,661,000 | +13.1% | 280,435 | -21.9% | 0.01% | 0.0% |
| Q1 2020 | $10,311,000 | -73.0% | 359,003 | -32.2% | 0.01% | -66.7% |
| Q4 2019 | $38,240,000 | -42.3% | 529,730 | +12.2% | 0.02% | -44.4% |
| Q3 2019 | $66,251,000 | -41.8% | 472,248 | -24.0% | 0.03% | -40.0% |
| Q2 2019 | $113,776,000 | +13332.8% | 621,425 | +11384.5% | 0.04% | +800.0% |
| Q2 2018 | $847,000 | -51.1% | 5,411 | -49.7% | 0.01% | -54.5% |
| Q1 2018 | $1,733,000 | +19.4% | 10,758 | +22.1% | 0.01% | +22.2% |
| Q4 2017 | $1,452,000 | +148.2% | 8,814 | -6.1% | 0.01% | +125.0% |
| Q3 2017 | $585,000 | +113.5% | 9,385 | +173.1% | 0.00% | +100.0% |
| Q2 2017 | $274,000 | -60.5% | 3,437 | -84.1% | 0.00% | -50.0% |
| Q1 2016 | $693,000 | -41.4% | 21,620 | +6.5% | 0.00% | -33.3% |
| Q4 2015 | $1,183,000 | +33.5% | 20,293 | -3.1% | 0.01% | +20.0% |
| Q3 2015 | $886,000 | – | 20,949 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |